THE CYP3A5 GENOTYPE HAS A MARKED IMPACT ON TACROLIMUS PHARMACOKINETICS BUT DOES NOT AFFECT MIDAZOLAM PHARMACOKINETICS IN A LARGE COHORT OF RENAL TRANSPLANT RECIPIENTS

被引：0
|
作者：
de Jonge, H. [1 ]
de Loor, H. [1 ]
Verbeke, K. [2 ]
Vanrenterghem, Y. [1 ]
Kuypers, D. R. [1 ]
机构：
[1] Katholieke Univ Leuven Hosp, Dept Nephrol & Renal Transplantat, Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Dept Gastrointestinal Res, Louvain, Belgium
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [31] Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation
    Fromm, Martin F.
    Schwilden, Helmut
    Bachmakov, Iouri
    Koenig, Joerg
    Bremer, Frank
    Schuettler, Juergen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (12) : 1129 - 1133
  • [32] Lack of Tacrolimus Circadian Pharmacokinetics and CYP3A5 Pharmacogenetics in the Early and Maintenance Stages in Renal Transplant Recipients.
    Satoh, Shigeru
    Saito, Mitsuru
    Kagaya, Hideaki
    Miura, Masatomo
    Inoue, Takamitsu
    Miura, Yoshio
    Numakura, Kazuyuki
    Kumazawa, Teruaki
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 590 - 590
  • [33] Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre
    Cheng, Y.
    Li, H.
    Meng, Y.
    Liu, H.
    Yang, L.
    Xu, T.
    Yu, J.
    Zhao, N.
    Liu, Y.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 : 16 - 22
  • [34] The impact of CYP3A5*3 and CYP3A4*22 polymorphisms on Tacrolimus pharmacokinetics in a caucasian kidney transplant cohort
    Abdel-Kahaar, E.
    Winter, S.
    Schaeffeler, E.
    Olbricht, C.
    Shipkova, M.
    Schwab, M.
    Wieland, E.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 : S74 - S74
  • [35] Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation
    Martin F. Fromm
    Helmut Schwilden
    Iouri Bachmakov
    Jörg König
    Frank Bremer
    Jürgen Schüttler
    European Journal of Clinical Pharmacology, 2007, 63 : 1129 - 1133
  • [36] Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients
    Satoh, Shigeru
    Kagaya, Hideaki
    Saito, Mitsuru
    Inoue, Takamitsu
    Miura, Masatomo
    Inoue, Kazuyuki
    Numakura, Kazuyuki
    Tsuchiya, Norihiko
    Tada, Hitoshi
    Suzuki, Toshio
    Habuchi, Tomonori
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (02) : 207 - 214
  • [37] The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients
    Zhang, Jing-Jing
    Liu, Shuai-Bing
    Xue, Ling
    Ding, Xiao-Liang
    Zhang, Hua
    Miao, Li-Yan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (09) : 728 - 736
  • [38] Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients
    Uno, Takaya
    Wada, Kyoichi
    Matsuda, Sachi
    Terada, Yuka
    Oita, Akira
    Kawase, Atsushi
    Takada, Mitsutaka
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (06) : 665 - 673
  • [39] Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients
    Takaya Uno
    Kyoichi Wada
    Sachi Matsuda
    Yuka Terada
    Akira Oita
    Atsushi Kawase
    Mitsutaka Takada
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 665 - 673
  • [40] IN VIVO CYP3A4-ACTIVITY AND CYP3A5-GENOTYPE PREDICT TACROLIMUS PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS.
    de Jonge, H.
    de Loor, H.
    Verbeke, K.
    Vanrenterghem, Y.
    Kuypers, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S50
12345